J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT

Johnson & Johnson's COVID-19 vaccine has taken a back seat to mRNA programs from Pfizer and Moderna in many developed nations, but it's still in high demand around the world. That's why news the company recently paused production came as a surprise to some people, including J&J's top customers. Late last year, Johnson & Johnson halted production of its COVID-19 vaccine from its facility in the Dutch city of Leiden, The New York Times reports. Thanks to vaccine stockpiles, it’s unclear whether the pause has affected vaccine supplies, the NYT notes. The pause is only temporary, with J&J gearing up to resume production in Leiden of its COVID shot in March